CORPORATE STRATEGY

Partnering strategy

Arrow's strategy is to focus on the early clinical development of its compounds and enter into collaborations with pharmaceutical companies for late stage development and commercialisation.

In-licensing and M&A

Arrow is interested in evaluating anti-infective in-licensing opportunities that have a clear strategic fit with our antiviral portfolio. To enquire about partnering (out-licensing and in-licensing) opportunities please contact Business Development.

We also actively consider M&A opportunities as a means of accelerating growth. To enquire about M&A opportunities please contact Finance.